[go: up one dir, main page]

NO20020886L - Novel integrin <alfa> v <beta> 3 inhibitors - Google Patents

Novel integrin <alfa> v <beta> 3 inhibitors

Info

Publication number
NO20020886L
NO20020886L NO20020886A NO20020886A NO20020886L NO 20020886 L NO20020886 L NO 20020886L NO 20020886 A NO20020886 A NO 20020886A NO 20020886 A NO20020886 A NO 20020886A NO 20020886 L NO20020886 L NO 20020886L
Authority
NO
Norway
Prior art keywords
alfa
inhibitors
beta
novel integrin
integrin
Prior art date
Application number
NO20020886A
Other languages
Norwegian (no)
Other versions
NO20020886D0 (en
Inventor
Alfred Jonczyk
Oliver Schadt
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20020886D0 publication Critical patent/NO20020886D0/en
Publication of NO20020886L publication Critical patent/NO20020886L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører nye forbindelser med formel (I) som er biologisk aktive når de er til stede som ligander for integrinet 0^3: X-Y-Z-R'-CH2R2(R4)-CH2-CO-R5 (I), hvor betydningen av X, Y, Z, R1, R2, R4 og R5 er an- gitt i krav l. Oppfinnelsen vedrører også fysiologisk akseptable salter og solvater av forbindelsene.The invention relates to novel compounds of formula (I) which are biologically active when present as ligands for the integrin 0 ^ 3: XYZ-R'-CH2R2 (R4) -CH2-CO-R5 (I), wherein the meaning of X, The invention also relates to physiologically acceptable salts and solvates of the compounds.

NO20020886A 1999-08-24 2002-02-22 Novel integrin <alfa> v <beta> 3 inhibitors NO20020886L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19939981A DE19939981A1 (en) 1999-08-24 1999-08-24 New inhibitors of the integrin alphavß3
PCT/EP2000/007591 WO2001014338A1 (en) 1999-08-24 2000-08-04 NOVEL INTEGRIN αVβ3 INHIBITORS

Publications (2)

Publication Number Publication Date
NO20020886D0 NO20020886D0 (en) 2002-02-22
NO20020886L true NO20020886L (en) 2002-02-22

Family

ID=7919343

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020886A NO20020886L (en) 1999-08-24 2002-02-22 Novel integrin <alfa> v <beta> 3 inhibitors

Country Status (17)

Country Link
EP (1) EP1206454A1 (en)
JP (1) JP2003507458A (en)
KR (1) KR20020016651A (en)
CN (1) CN1370147A (en)
AU (1) AU6570500A (en)
BR (1) BR0013504A (en)
CA (1) CA2382850A1 (en)
CZ (1) CZ2002523A3 (en)
DE (1) DE19939981A1 (en)
HK (1) HK1049666A1 (en)
HU (1) HUP0203697A3 (en)
MX (1) MXPA02001861A (en)
NO (1) NO20020886L (en)
PL (1) PL352989A1 (en)
SK (1) SK2282002A3 (en)
WO (1) WO2001014338A1 (en)
ZA (1) ZA200202287B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
WO2005056575A2 (en) * 2003-12-03 2005-06-23 The Scripps Research Institute INTEGRIN αIIbβ3 SPECIFIC ANTIBODIES AND PEPTIDES
BRPI0419110A (en) * 2004-10-14 2007-12-11 Pharmacia Corp biphenyl integrin antagonists
WO2018089360A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325264A (en) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd Novel 2-aromatic ring-substituted-3-phenylpropionic acid or acrylic acid derivative
AU717283B2 (en) * 1996-10-30 2000-03-23 Merck & Co., Inc. Integrin antagonists
OA12189A (en) * 1998-03-10 2006-05-09 Smithkline Beecham Corp Vitronectin receptor antagonists.

Also Published As

Publication number Publication date
CA2382850A1 (en) 2001-03-01
CZ2002523A3 (en) 2002-05-15
SK2282002A3 (en) 2002-06-04
MXPA02001861A (en) 2004-09-06
ZA200202287B (en) 2003-08-27
WO2001014338A1 (en) 2001-03-01
AU6570500A (en) 2001-03-19
PL352989A1 (en) 2003-09-22
DE19939981A1 (en) 2001-03-01
NO20020886D0 (en) 2002-02-22
JP2003507458A (en) 2003-02-25
HK1049666A1 (en) 2003-05-23
HUP0203697A3 (en) 2004-04-28
EP1206454A1 (en) 2002-05-22
HUP0203697A2 (en) 2003-03-28
CN1370147A (en) 2002-09-18
KR20020016651A (en) 2002-03-04
BR0013504A (en) 2002-05-07

Similar Documents

Publication Publication Date Title
NL350075I2 (en)
TR200101744T2 (en) Phenylglycine derivatives.
IL148903A0 (en) Certain alkylene diamine-substituted heterocycles
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
YU69501A (en) Glucokinase activators
TR200000333T2 (en) 4-aminopyrol (3,2-d) pyrimidines as Y receptor antagonists.
NO996108L (en) 9 oksinerytromycinderivater
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
EP1396493A4 (en) Heterocyclic compounds
DE60112330D1 (en) Pyrazolopyridinderivate
SE9904108D0 (en) New compounds
CA2336412A1 (en) Medicament for treatment of diabetes
DK1077218T3 (en) Peptidomimetic compounds comprising RGD sequences useful as integrin inhibitors
TR200201128T2 (en) Tetrahydrothiopyraniphalazinone derivatives as PDE4 inhibitors.
TR200302288T2 (en) New compounds and methods for therapy.
NO981393L (en) Guanidinoproteasehemmere
YU33202A (en) Oxime o-ether compounds and fungicides for agricultural and horticultural use
NO20022123L (en) Oxoxazole derivatives for use as inhibitors of phosphodiesterase VII
NO20020886L (en) Novel integrin &lt;alfa&gt; v &lt;beta&gt; 3 inhibitors
NO20020885L (en) &lt;Alpha&gt; v &lt;beta&gt; 3-integrin
MXPA02001406A (en) Substituted heterocyclyl-2h-chromenes.
DE69906243D1 (en) 2-indanemethanol derivatives and their use as fragrances
AP2001002314A0 (en) Substituted benzolactam compounds.
PL345966A1 (en) N-substituted azabicycloheptane derivatives, production and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application